ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein
ANEW MEDICAL (NASDAQ: WENA) has secured a key patent in Europe (EP3377091B1) for its secreted Klotho gene (s-KL) and gene delivery systems, targeting neurodegenerative diseases like dementia and Alzheimer's. This patent complements earlier approvals in China and Hong Kong. The intellectual property was exclusively licensed from institutions in Barcelona, Spain. ANEW plans to leverage this patent for product development and expand into Asian markets starting in 2024. CEO Dr. Joseph Sinkule emphasized the potential of s-KL for cell and gene therapy in treating neurological disorders, noting its critical role in brain function and neurological health.
- ANEW MEDICAL secured a key patent in Europe for its Klotho gene delivery systems.
- The patent enhances ANEW's intellectual property portfolio in major global markets.
- Plans to expand product development into Asian markets beginning in 2024.
- Patent complements previous approvals in China and Hong Kong, broadening market reach.
- None.
ANEW Medical's recent patent approval in Europe for the secreted Klotho (s-KL) gene sequence and gene delivery system is important in the biopharmaceutical field. The s-KL protein's role in brain function and its potential application in neurodegenerative diseases like Alzheimer's and Parkinson's demonstrates significant progress in biotechnology. The patent enhances ANEW's intellectual property portfolio, providing a competitive advantage in the European market, potentially leading to lucrative opportunities in diagnostics and therapeutics. This patent, along with existing approvals in China and Hong Kong, reflects a strategic expansion into global markets.
This move may attract collaborations or licensing deals, boosting the company's growth and potentially enhancing its stock value. Investors should watch how effectively ANEW capitalizes on these patents and advances their product development pipeline.
From a financial perspective, securing this patent in Europe solidifies ANEW Medical's intellectual property assets and could be seen as a positive signal for investors. The exclusive rights to a novel therapeutic approach for neurodegenerative diseases could open substantial revenue streams, especially considering the rising prevalence of these conditions globally. The patents in China and Hong Kong also indicate a strategic move to tap into the Asian market, potentially increasing their market footprint.
However, it is essential to consider the costs associated with bringing these therapies to market. Research and development, regulatory approvals and commercialization will require significant investment. The company's ability to manage these costs and successfully bring products to market will be critical for sustained financial growth.
The patent approval for the s-KL gene sequence in Europe is a notable milestone for ANEW Medical. The global market for neurodegenerative disease therapies is expanding rapidly, driven by an aging population and increasing awareness of these conditions. ANEW's focus on innovative treatments differentiates it within this competitive landscape. The company's strategic expansion into Asian markets further underscores its growth potential.
For retail investors, monitoring the market acceptance of ANEW's therapies and the competitive response from other biopharmaceutical companies is crucial. Success in clinical trials and positive regulatory feedback will be key indicators of potential market performance.
- ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest
- Exclusive, worldwide intellectual property licensed from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW” or “the Company”) a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics, announces that is has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW’s secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.
This key intellectual property asset was licensed on an exclusive worldwide basis by ANEW from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain. On March 4, 2024, the Company previously announced patent approval in China (CN108289933B) and is now approved in Hong Kong (HK1259628A1) as well. ANEW plans to begin product development and expand their intellectual property portfolios into the Asian markets beginning in 2024.
Dr. Joseph Sinkule, Founder and CEO of ANEW MEDICAL, commented: “We feel strongly about the significant potential of this therapy and have taken meticulous steps to protect and expand our licensed intellectual property in major global markets. These assets play a vital role in our international product development efforts for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and ALS (Lou Gehrig’s disease). We believe our secreted Klotho RNA splice variant (“s-KL”) programs for cell and gene therapy, along with the related protein and genomics diagnostic programs, represent a groundbreaking approach to identifying and treating these devastating diseases.”
Dr. Sinkule, continues: “There are two proteins transcribed from the human Klotho gene, s-KL is the RNA splice variant made from the gene. It differs from the full-length Klotho protein transcribed from the gene as it is made by cells primarily in the kidneys and controls phosphate and calcium ion homeostasis in the body. Our studies show that s-KL protein is made predominantly by cells in the human brain and is extremely important in brain function and in the maintenance of normal neurologic function throughout the central nervous system (CNS) and peripheral nervous system. As we advance the program, ANEW will explore diagnostics and therapeutics utilizing the s-KL protein and its interactions with other human proteins and 'genes of interest.' We will also pursue other medical product development and commercial opportunities.”
About ANEW MEDICAL, INC.:
ANEW MEDICAL is a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics. The company's focus on central nervous systems (CNS) diseases utilizing cell and gene therapies to mitigate age-related pathologies such as Alzheimer's disease, dementia symptoms and neuromuscular diseases. The Company has exclusive worldwide rights to develop and commercialize proprietary product platforms based on its proprietary isoform transcribed from the human Klotho gene referred to as secreted Klotho or “s-KL”. This s-KL protein or gene therapy has been recognized for its potential to mitigate age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease. The Company is also evaluating other core technology platforms to acquire for development and commercialization by the Company. For more information, please visit: www.anewmeds.com.
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For more information, contact:
Investor Relations
Jeff Ramson or Adam Holdsworth
Email: ir@anewmeds.com
Website: www.anewmeds.com
FAQ
What recent patent did ANEW MEDICAL (WENA) secure?
How will the new patent impact ANEW MEDICAL's (WENA) business?
What diseases is ANEW MEDICAL (WENA) targeting with its new patent?
What regions have approved ANEW MEDICAL's (WENA) Klotho gene-related patents?
